<DOC>
	<DOCNO>NCT02990325</DOCNO>
	<brief_summary>The purpose ABX464-005 study characterize systemic mucosal immunological sequela associate exposure ABX464 explore select immunological endpoint , compartmental pharmacokinetics , pharmacodynamics .</brief_summary>
	<brief_title>A Safety , Pharmacokinetics , Pharmacodynamics Study ABX464 HIV-1 Seronegative Seropositive Adults</brief_title>
	<detailed_description>The purpose ABX464-005 study characterize systemic mucosal immunological sequela associate exposure ABX464 explore select immunological endpoint , compartmental pharmacokinetics , pharmacodynamics . The site screen enroll 12 HIV-infected subject receive 150 mg ABX464 orally daily 28 day ( Cohort 1 ) . Following completion cohort 24 subject enrol ( 12 HIV-infected 12 HIV-uninfected ) receive 150 mg ABX464 orally daily 28 day . ( Cohort 2 )</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<criteria>Inclusion criterion : Males age 1865 year ; Subjects adequate hematological biochemical laboratory parameter Subjects able willing comply study visit procedure per protocol ; Subjects understand , sign date write voluntary informed consent form screen visit prior protocolspecific procedure perform ; Subjects must agree use addition condom , second highly effective method ( one subject one partner ) contraception ( define per CTFG Guidance ) . For HIV positive Subjects Subjects positive HIV1 serology time study entry . Subjects treat least 12 month prior screen Dolutegravir Raltegravir combine either Tenofovir + Emtricitabine ( TDF/FTC ) Abacavir + Lamivudine ( ABC/3TC ) ; Subjects HIV plasma viral load ≤ 50 copies/mL 6 month prior screen maximum 2 blip ≤ 1000 copy period ; Subjects ' HIV1 plasma viral load ≤ 100,000 copies/mL time beyond 6 month estimate date primary infection ; History allergic disease , anaphylaxis reaction likely trigger exacerbated component investigational product ; Acute chronic infectious disease HIV infection ( include limit viral hepatitis hepatitis B , hepatitis C , active tuberculosis , active syphilis [ i.e . currently treat ] , HTLV1 , HTLV2 ) . Acute , chronic history clinically relevant pulmonary , cardiovascular , gastrointestinal , hepatic , pancreatic renal functional abnormality , encephalopathy , neuropathy unstable CNS pathology , angina cardiac arrhythmia , clinically significant medical problem determine physical examination and/or laboratory screen test and/or medical history ; Severe hepatic impairment ; Acute , chronic history immunodeficiency autoimmune disease HIV infection ;</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>ABX464 , HIV infection</keyword>
</DOC>